CRIS Current Research Information System

ZAMAGNI, ELENA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 12.755
NA - Nord America 12.554
EU - Europa 8.042
Continente sconosciuto - Info sul continente non disponibili 772
SA - Sud America 759
AF - Africa 655
OC - Oceania 27
Totale 35.564
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 12.229
CN - Cina 3.470
SG - Singapore 3.213
VN - Vietnam 3.133
IT - Italia 2.304
GB - Regno Unito 1.495
DE - Germania 886
SE - Svezia 762
HK - Hong Kong 759
BR - Brasile 539
FR - Francia 528
IN - India 508
BD - Bangladesh 458
KR - Corea 433
NL - Olanda 393
RU - Federazione Russa 371
IE - Irlanda 260
UA - Ucraina 221
FI - Finlandia 219
JP - Giappone 207
CI - Costa d'Avorio 187
ZA - Sudafrica 156
CA - Canada 146
SC - Seychelles 104
EE - Estonia 101
TG - Togo 100
AR - Argentina 96
PH - Filippine 85
AT - Austria 77
BG - Bulgaria 69
CH - Svizzera 68
TH - Thailandia 68
MX - Messico 64
ES - Italia 63
ID - Indonesia 57
BE - Belgio 50
PL - Polonia 50
TR - Turchia 47
IQ - Iraq 45
JO - Giordania 44
EC - Ecuador 36
TW - Taiwan 33
SA - Arabia Saudita 28
CO - Colombia 25
JM - Giamaica 25
EG - Egitto 24
AU - Australia 23
CZ - Repubblica Ceca 23
IR - Iran 23
GR - Grecia 22
PK - Pakistan 22
NG - Nigeria 20
CL - Cile 18
GT - Guatemala 16
MY - Malesia 16
UZ - Uzbekistan 16
LB - Libano 15
MA - Marocco 15
IL - Israele 14
VE - Venezuela 14
RO - Romania 13
KE - Kenya 11
LT - Lituania 11
TN - Tunisia 11
TT - Trinidad e Tobago 11
PY - Paraguay 10
SV - El Salvador 10
CR - Costa Rica 9
HN - Honduras 9
NI - Nicaragua 9
UY - Uruguay 9
DO - Repubblica Dominicana 8
AE - Emirati Arabi Uniti 7
AL - Albania 7
DZ - Algeria 7
KZ - Kazakistan 7
NP - Nepal 7
OM - Oman 7
PT - Portogallo 7
AZ - Azerbaigian 6
HR - Croazia 6
PE - Perù 6
RS - Serbia 6
CY - Cipro 5
ET - Etiopia 5
NO - Norvegia 5
PR - Porto Rico 5
BO - Bolivia 4
HU - Ungheria 4
KG - Kirghizistan 4
LV - Lettonia 4
QA - Qatar 4
BZ - Belize 3
GH - Ghana 3
MK - Macedonia 3
SK - Slovacchia (Repubblica Slovacca) 3
SN - Senegal 3
A2 - ???statistics.table.value.countryCode.A2??? 2
AO - Angola 2
BS - Bahamas 2
Totale 34.748
Salva come PNG Salva come JPEG
Città #
Singapore 2.260
Ashburn 1.416
Southend 1.227
Fairfield 1.031
Hefei 908
Chandler 827
Hong Kong 722
Ho Chi Minh City 719
San Jose 625
Hanoi 612
Woodbridge 485
Bologna 457
Seattle 454
Dallas 414
Houston 413
Wilmington 413
Seoul 393
Beijing 392
Cambridge 350
Ann Arbor 343
Santa Clara 334
Council Bluffs 311
Princeton 308
Dong Ket 286
New York 266
Boardman 257
Dublin 255
Los Angeles 239
Lauterbourg 210
Milan 192
Abidjan 187
Tokyo 171
Helsinki 159
Jacksonville 126
Nanjing 121
Buffalo 113
Westminster 113
Haiphong 109
Padova 103
Berlin 102
Lomé 100
Frankfurt am Main 92
Bengaluru 88
São Paulo 86
Rome 84
Da Nang 81
Turin 81
Bremen 80
Munich 78
Jinan 76
Guangzhou 74
San Diego 73
Shanghai 71
Chicago 67
Sofia 67
Redondo Beach 64
Tianjin 63
Shenyang 61
Saint Petersburg 60
Hyderabad 58
Changsha 56
Amsterdam 53
Florence 51
Redwood City 51
Brussels 46
Nuremberg 45
Phoenix 45
Amman 44
Lappeenranta 43
Naples 43
Vienna 42
Zhengzhou 42
London 41
Nanchang 41
Shenzhen 41
Toronto 41
Redmond 40
Johannesburg 38
Bern 37
Can Tho 37
San Francisco 37
Jakarta 36
Brooklyn 33
Hangzhou 33
Hải Dương 33
Orem 33
Warsaw 33
Falls Church 32
Hebei 32
Biên Hòa 31
Atlanta 30
Falkenstein 30
Montreal 30
Paris 30
Washington 30
Mexico City 28
Wuhan 28
Medford 27
Modena 27
Des Moines 26
Totale 21.423
Salva come PNG Salva come JPEG
Nome #
Clonal and subclonal TP53 molecular impairment is associated with prognosis and progression in multiple myeloma 719
18F-FDG PET/CT focal, but not osteolytic, lesions predict the progression of smoldering myeloma to active disease 359
BoBafit: A copy number clustering tool designed to refit and recalibrate the baseline region of tumors’ profiles 335
A prospective comparison of 18F-fluorodeoxyglucose positron emission tomography-computed tomography, magnetic resonance imaging and whole-body planar radiographs in the assessment of bone disease in newly diagnosed multiple myeloma. 314
Bortezomib-based therapy combined with high cut-off hemodialysis is highly effective in newly diagnosed multiple myeloma patients with severe renal impairment 272
Prediction of response to primary therapy with thalidomide-dexamethasone (thal-dex) for newly diagnosed multiple myeloma by gene expression profiling (gep) 256
Peripheral neuropathy induced by subcutaneous bortezomib-based induction therapy for newly diagnosed multiple myeloma. 251
Positron emission tomography with computed tomography-based diagnosis of massive extramedullary progression in a patient with high-risk multiple myeloma. 250
A NEW RISK STRATIFICATION STRATEGY IN NEWLY DIAGNOSED MULTIPLE MYELOMA: AN ANALYSIS ON MATURE DATA FROM EUROPEAN CLINICAL TRIALS WITHIN THE HARMONY BIG DATA PLATFORM 245
Standardization of 18F-FDG-PET/CT According to Deauville Criteria for Metabolic Complete Response Definition in Newly Diagnosed Multiple Myeloma 239
Treatment optimization for Multiple Myeloma: schedule-dependent synergistic cytotoxicity of pomalidomide and carfilzomib in an in vitro and ex-vivo model 238
Bortezomib and dexamethasone as salvage therapy in patients with relapsed/refractory multiple myeloma: analysis of long-term clinical outcomes 237
The genetic and genomic background of multiple myeloma patients achieving complete response after induction therapy with bortezomib, thalidomide and dexamethasone (VTD) 237
A new risk stratification model (R2-ISS) in Newly Diagnosed Multiple Myeloma: Analysis of Mature Data from 7077 patients collected by European Myeloma Network Within HARMONY Big Data Platform 235
Assessmen of disease ativity in multiple myeloma with FDG-PET imaging 226
CLINICAL OUTCOMES PREDICTION FOR NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS TREATED WITH THALIDOMIDE-DEXAMETHASONE AND AUTOLOGOUS STEM CELL TRANSPLANTATION BY 8-GENE SIGNATURE OF CD138+ PLASMA CELLS 226
The role of positron emission tomography-computed tomography and magnetic resonance imaging in diagnosis and follow up of multiple myeloma. 224
Idecabtagene vicleucel (ide-cel) for the treatment of triple-class exposed relapsed and refractory multiple myeloma 223
Safety and efficacy of daratumumab in dialysis-dependent renal failure secondary to multiple myeloma 222
Current and emerging triplet combination therapies for relapsed and refractory multiple myeloma 221
Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study. 221
Thalidomide alone or in combination with dexamethasone in patients with advanced, relapsed or refractory multiple myeloma and renal failure. 220
Bortezomib- and thalidomide-induced peripheral neuropathy in multiple myeloma: clinical and molecular analyses of a phase 3 study. 218
Clinical Presentation and Long‐Term Survival Outcomes of Patients With Monoclonal Gammopathy of Renal Significance (MGRS): A Multicenter Retrospective Study 213
Identification of a Maturation Plasma Cell Index through a Highly Sensitive Droplet Digital PCR Assay Gene Expression Signature Validation in Newly Diagnosed Multiple Myeloma Patients 213
Efficacy and Prognostic Indicators of Isatuximab, Pomalidomide, and Dexamethasone (IsaPd) in Daratumumab-Refractory Multiple Myeloma Patients: A Multicenter Real-World Study 213
Bortezomib, thalidomide, and dexamethasone followed by double autologous haematopoietic stem-cell transplantation for newly diagnosed multiple myeloma (GIMEMA-MMY-3006): long-term follow-up analysis of a randomised phase 3, open-label study 213
A real-world efficacy and safety analysis of combined carfilzomib, lenalidomide, and dexamethasone (KRd) in relapsed/refractory multiple myeloma 213
A Comparison of Different Staging Systems for Multiple Myeloma: Can the MRI Pattern Play a Prognostic Role? 212
Inter-Cell Networking Profiling Enables Comprehensive Characterization of Immune-Mediated Activity of Anti-CD38 Therapy through Ex-Vivo Analysis of Multiple Myeloma Patients 210
11C-choline vs. 18F-FDG PET/CT in assessing bone involvement in patients with multiple myeloma. 209
Circulating Multiple Myeloma Cells (CMMCs) as Prognostic and Predictive Markers in Multiple Myeloma and Smouldering MM Patients 208
HIF-1α inhibition blocks the cross talk between multiple myeloma plasma cells and tumor microenvironment 206
Interpretation criteria for FDG PET/CT in multiple myeloma (IMPeTUs): final results. IMPeTUs (Italian myeloma criteria for PET USe) 206
Prognostic impact of serial measurements of serum-free light chain assay throughout the course of newly diagnosed multiple myeloma treated with bortezomib-based regimens 205
Novel agent-based salvage autologous stem cell transplantation for relapsed multiple myeloma 205
Autologous haematopoietic stem-cell transplantation versus bortezomib–melphalan–prednisone, with or without bortezomib–lenalidomide–dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study 205
Bortezomib-thalidomide-dexamethasone (VTD) is superior to bortezomib-cyclophosphamide-dexamethasone (VCD) as induction therapy prior to autologous stem cell transplantation in multiple myeloma 204
European Myeloma Network Group review and consensus statement on primary plasma cell leukemia 203
Superiority of thalidomide and dexamethasone over vincristine-doxorubicindexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myeloma. 202
Successful mobilization of PBSCs predicts favorable outcomes in multiple myeloma patients treated with novel agents and autologous transplantation 202
Use of FDG-PET imaging for assessment of disease activity in patients with multiple myeloma 201
First-line therapy with thalidomide, dexamethasone and zoledronic acid decreases bone resorption markers in patients with multiple myeloma. 201
Opposite activation of the Hedgehog pathway in CD138+ plasma cells and CD138-CD19+ B cells identifies two subgroups of patients with multiple myeloma and different prognosis 201
Hypoxia inducible factor-1 alpha as a therapeutic target in multiple myeloma. 199
Complete remission upon bortezomib-dexamethasone therapy in three heavily pretreated multiple myeloma patients relapsing after allogeneic stem cell transplantation. 198
Evaluation of bone disease in multiple myeloma patients carrying the t(4;14) chromosomal translocation. 197
Systemic cardiac amyloidoses: disease profiles and clinical courses of the 3 main types. 197
Diagnostic Innovations: Advances in imaging techniques for diagnosis and follow-up of multiple myeloma 196
The ALLgorithMM: How to define the hemodilution of bone marrow samples in lymphoproliferative diseases 194
Aspirin, warfarin, or enoxaparin thromboprophylaxis in patients with multiple myeloma treated with thalidomide: a phase III, open-label, randomized trial. 193
Image interpretation criteria for FDG PET/CT in multiple myeloma: a new proposal from an Italian expert panel. IMPeTUs (Italian Myeloma criteria for PET USe) 193
Role of serum-free light chain assay for defining response and progression in immunoglobulin secretory multiple myeloma 192
Contrast enhanced MRI and (18)F-FDG PET-CT in the assessment of multiple myeloma: a comparison of results in different phases of the disease 191
Maintenance therapy with bortezomib and dexamethasone after autotransplantation for high-risk multiple myeloma 188
Short-term thalidomide incorporated into double autologous stem-cell transplantation improves outcomes in comparison with double autotransplantation for multiple myeloma. 187
Thalidomide maintenance in multiple myeloma: certainties and controversies. 185
High level of circulating cell-free tumor DNA at diagnosis correlates with disease spreading and defines multiple myeloma patients with poor prognosis 184
Thalidomide-dexamethasone as induction therapy before autologous stem cell transplantation in patients with newly diagnosed multiple myeloma and renal insufficiency. 183
Combination of international scoring system 3, high lactate dehydrogenase, and t(4;14) and/or del(17p) identifies patients with multiple myeloma (MM) treated with front-line autologous stem-cell transplantation at high risk of early MM progression-related death. 183
PET/CT Improves the Definition of Complete Response and Allows to Detect Otherwise Unidentifiable Skeletal Progression in Multiple Myeloma 182
Long-term results of thalidomide and dexamethasone (thal-dex) as therapy of first relapse in multiple myeloma. 181
Bortezomib-thalidomide-dexamethasone is superior to thalidomide-dexamethasone as consolidation therapy following autologous hematopoietic stem-cell transplantation in patients with newly diagnosed multiple myeloma. 181
Adjusted comparison between elotuzumab and carfilzomib in combination with lenalidomide and dexamethasone as salvage therapy for multiple myeloma patients 181
Poor outcome with front-line autologous transplantation in t(4;14) multiple myeloma: low complete remission rate and short duration of remission. 180
Inverse probability weighting to estimate causal effect of a singular phase in a multiphase randomized clinical trial for multiple myeloma 179
Oxytocin Modulates Osteogenic Commitment in Human Adipose-Derived Stem Cells 178
Unique molecular assay (UMA): a next-generation sequencing targeted panel for efficient and comprehensive genomic profiling and risk stratification of multiple myeloma 178
Additional copies of 1q negatively impact the outcome of multiple myeloma patients and induce transcriptomic deregulation in malignant plasma cells 177
Dermoscopy of cutaneous involvement by multiple myeloma 177
Role of serum free light chain assay in the detection of early relapse and prediction of prognosis after relapse in multiple myeloma patients treated upfront with novel agents 177
HIF 1 Alpha: A Suitable Target for Multiple Myeloma 177
Anti-CD38 and anti-SLAMF7: the future of myeloma immunotherapy 177
Long term follow-up of humoral and cellular response to mRNA-based vaccines for SARS-CoV-2 in patients with active multiple myeloma 176
Second Revision of the International Staging System (R2-ISS) for Overall Survival in Multiple Myeloma: A European Myeloma Network (EMN) Report Within the HARMONY Project 173
Single-Cell DNA Sequencing Reveals an Evolutionary Pattern of CHIP in Transplant Eligible Multiple Myeloma Patients 172
Comparison between 18F-FDG PET/CT and 11C-Choline PET/CT for the evaluation of multiple myeloma 171
Extramedullary disease in multiple myeloma: a systematic literature review 170
Diagnosis, treatment, and response assessment in solitary plasmacytoma: Updated recommendations from a European Expert Panel 170
The role of imaging techniques in the management of multiple myeloma 169
High Number of Copy Number Alterations and Over-Expression of Genes Involved in the Response Mechanisms to Genotoxic Stress Both Characterize Newly Diagnosed Multiple Myeloma (MM) Patients Carrying Amplified MDM4 and/or Deleted p53 169
From transplant to novel cellular therapies in multiple myeloma: EMN guidelines and future perspectives 168
Outcomes and prognostic indicators in daratumumab-refractory multiple myeloma: a multicenter real-world study of elotuzumab, pomalidomide, and dexamethasone in 247 patients 166
Early use of PEPA dialyzer for light chains removal and for the recovery from myeloma cast nephropathy: A case report 166
18F-FDG PET/CT in myeloma with presumed solitary plasmocytoma of bone. 165
Genomic characterization of the putative myeloma stem cells clone reveals alterations possibly correlated with the origin of disease. 165
First-line therapy with thalidomide and dexamethasone in preparation for autologous stem cell transplantation for multiple myeloma. 165
Early Light Chains Removal and Albumin Levels with a Double Filter-Based Extracorporeal Treatment for Acute Myeloma Kidney 164
Gene expression analysis of newly diagnosed Multiple Myeloma (MM) patients carrying amplified MDM4 and/or deleted p5 164
IMWG consensus on risk stratification in multiple myeloma. 164
Report of the 6th International Workshop on PET in lymphoma 164
Oxytocin modulates osteogenic commitment in human adipose-derived mesenchymal stem cells 163
Neurological toxicity of long-term (>1 yr) thalidomide therapy in patients with multiple myeloma. 163
Isatuximab, pomalidomide, and dexamethasone as salvage therapy for patients with multiple myeloma: the Italian, multicenter, retrospective clinical experience with 270 cases outside of controlled clinical trials 162
Multidisciplinary Management of Sternal Osteomyelitis Due to Klebsiella aerogenes after Open Heart Surgery in a Patient with Multiple Myeloma: A Case Report and Discussion of the Literature 162
Role of 18F-FDG PET/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: a consensus statement by the International Myeloma Working Group 162
OAB-006: A novel algorithm to identify, characterize and define the prognostic impact of complex catastrophic events in Multiple Myeloma 160
Maintenance therapy in newly diagnosed multiple myeloma: current recommendations. 160
Correlation between eight-gene expression profiling and response to therapy of newly diagnosed multiple myeloma patients treated with thalidomide–dexamethasone incorporated into double autologous transplantation 159
Belantamab mafodotin: an important treatment option for vulnerable patients with triple class exposed relapsed and/or refractory multiple myeloma 158
Totale 20.388
Salva come PNG Salva come JPEG
Categoria #
all - tutte 101.472
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 101.472
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20222.629 0 124 186 197 273 140 80 217 139 234 545 494
2022/20233.458 347 528 154 508 228 280 111 193 548 133 262 166
2023/20241.310 82 182 96 99 115 261 75 123 34 93 84 66
2024/20255.039 209 568 422 411 522 266 429 170 135 505 403 999
2025/202614.669 1.253 1.886 1.358 1.062 1.323 736 1.212 503 2.553 1.129 968 686
2026/20271.188 558 630 0 0 0 0 0 0 0 0 0 0
Totale 35.564